The "Middle East Cell and Gene Therapy CDMO Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.
The Middle East Cell and Gene Therapy CDMO market is poised for significant growth, with its market size expected to surge from USD 55.68 million in 2024 to USD 184.18 million by 2033, exhibiting a CAGR of 14.23% from 2025 to 2033. Key drivers include increased investments in advanced therapeutics, a rising prevalence of genetic disorders, robust government support for biotech innovation, and a growing demand for specialized manufacturing services.
Regional governments, notably the UAE and Saudi Arabia, are making strategic investments in life sciences and precision medicine under initiatives like Saudi Vision 2030. These initiatives bolster local capabilities in contract development and manufacturing by fostering biotech hubs and public-private partnerships. Coupled with a surge in rare genetic disorders and cancers, there is a marked shift towards outsourcing complex manufacturing processes to specialized CDMOs that offer gene-modified therapies, viral vector production, and cell engineering solutions.
Further stimulating market expansion are strategic alliances between regional healthcare systems and global pharmaceutical entities. By collaborating with local CDMOs and research bodies, companies are accelerating clinical development, ramping up production, and facilitating market entry. Meanwhile, regional regulatory authorities are streamlining approval processes for advanced therapies, reinforcing GMP-compliant environments, and establishing centralized frameworks for clinical trials, further propelling market growth.
The companies profiled in this Middle East Cell and Gene Therapy CDMO market report include:
- Porton Pharma Solutions, Ltd. (Porton Advanced)
- WuXi AppTec
- Thermo Fisher Scientific, Inc.
- Charles River Laboratories
- Lonza
- AGC Biologics
- Catalent
- Samsung Biologics
- OmniaBio
- Rentschler Biopharma SE
Middle East Cell and Gene Therapy CDMO Market Report Segmentation
This market report forecasts revenue growth at regional levels and provides an analysis of industry trends in each sub-segment from 2021 to 2033. It details segmentation by phase, product, indication, and country, offering a comprehensive view of market dynamics.
-
Phase Outlook (Revenue, USD Million, 2021-2033):
- Pre-clinical
- Clinical
-
Product Outlook (Revenue, USD Million, 2021-2033):
- Gene Therapy
- Gene-Modified Cell Therapy
- Cell Therapy
-
Indication Outlook (Revenue, USD Million, 2021-2033):
- Oncology
- Infectious Diseases
- Neurological Disorders
- Rare Diseases
- Others
-
Regional Outlook (Revenue, USD Million, 2021-2033):
- Middle East
Why You Should Buy This Report:
- Comprehensive Market Analysis: Gain detailed insights into major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover pivotal trends and drivers shaping the market's future.
- Actionable Recommendations: Uncover new revenue streams and guide strategic business decisions.
Report Deliverables:
- Market intelligence for effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings to stay ahead of the curve
Key Attributes
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $55.68 Million |
| Forecasted Market Value (USD) by 2033 | $184.18 Million |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Middle East |
For more information about this report visit https://www.researchandmarkets.com/r/bqlm3y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202399512/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900